Director at BridgeBio Oncology (BBOT) receives 7,289 stock options
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics director Peter F. Lebowitz received a grant of stock options covering 7,289 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036. According to the terms, they vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, provided he continues serving the company through that vesting date. After this grant, Lebowitz holds 7,289 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Lebowitz Peter F
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 7,289 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 7,289 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 7,289 options
Exercise price: $7.73 per share
Expiration date: June 15, 2036
+2 more
5 metrics
Option grant size
7,289 options
Stock Option (Right to Buy) granted to director on June 16, 2026
Exercise price
$7.73 per share
Conversion or exercise price for the 7,289 stock options
Expiration date
June 15, 2036
Expiration of the granted stock options
Underlying shares
7,289 shares
Common stock underlying the stock option grant
Post-grant derivative holdings
7,289 options
Total stock options held directly after the transaction
Key Terms
Stock Option (Right to Buy), Common Stock, Annual Meeting of Stockholders, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
vesting financial
"The shares underlying the stock option vest in full upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did BridgeBio Oncology Therapeutics (BBOT) disclose in this Form 4?
BridgeBio Oncology Therapeutics reported a director stock option grant for 7,289 shares. The options were awarded to Peter F. Lebowitz as compensation and give him the right to buy common stock at a fixed exercise price of $7.73 per share.
Who is the insider involved in the BBOT stock option grant?
The insider is Peter F. Lebowitz, a director of BridgeBio Oncology Therapeutics. He received a grant of stock options for 7,289 underlying common shares, held directly, as part of his service-related compensation with the company’s board.
What are the key terms of Peter Lebowitz’s BBOT stock options?
The stock options cover 7,289 shares of common stock at a $7.73 exercise price. They expire on June 15, 2036 and vest in full once a specific service-based vesting condition tied to time and the next Annual Meeting is met.
When do the BBOT stock options granted to Peter Lebowitz vest?
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders. Vesting is contingent on Peter Lebowitz continuing to serve the company through the applicable vesting date.
How many BBOT derivative securities does Peter Lebowitz hold after this Form 4?
Following this transaction, Peter Lebowitz directly holds stock options covering 7,289 shares of BridgeBio Oncology common stock. This single grant represents his reported derivative holdings in this filing, with no additional option positions listed.
Does this BBOT Form 4 show any stock being bought or sold on the market?
No open-market buys or sells are reported. The Form 4 records a grant of stock options to director Peter Lebowitz as compensation, giving him future purchase rights rather than showing an immediate market purchase or sale of common shares.